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Introduction
Antibiotic resistance (AR) has grown into a major global 
health problem over the past three to four decades. Over the 
same period, many warnings about the dangers of emerging 
AR have been issued, but these have not yet resulted in 
improvement of the current treatment options for bacterial 
infections. Only in the last decade or two have national and 
international agencies (like the European Centre for Disease 
Prevention and Control [ECDC] and World Health 
Organization [WHO])1,2 proposed and implemented actual 
policy changes to address AR, such as strengthening pru-
dent use of antibiotics (especially in veterinary medicine), 
improving surveillance and diagnostics, and increasing 
awareness of the need for the development of new antibiotic 
drugs.
The incidence of AR is increasing according to recent 
reports.3,4 Of particular concern is resistance to last-resort 
drugs like carbapenems, cephalosporins, and polymyxins in 
hospitals. There are also hints of transferability of multiple 
resistance genes outside the clinic.5,6 Lastly, the incidence 
of multi-drug-resistant Mycobacterium tuberculosis infec-
tions outside the clinic is also increasing.7 Tuberculosis 
(TB) is often discussed separately because of its differing 
disease and treatment characteristics.
One of the biggest current problems is that the clinical 
pipelines do not contain innovative new compounds to 
address this rising AR.8,9 This is often attributed to low 
incentives for development (any new antibiotic would be 
used as little as possible to avoid the generation of resis-
tance)10 and technical hurdles compared with other diseases 
(discussed later in this review).11 The most recent new class 
of marketed broad-spectrum antibiotics (oxazolidinones) 
was discovered in the early 1980s,12 and the most recent 
first-in-class narrow-spectrum antibiotic to be marketed 
(anti-TB synthetic diarylquinoline) was discovered around 
the turn of the millennium.13
This somewhat bleak picture of the current state of anti-
biotics development reveals the need for increased basic 
research efforts and antibiotic discovery programs that can 
feed into the clinical pipeline. Current research does offer 
many promising new concepts and ideas to work with. 
Some examples are systematic screening for inhibitors of 
apparently nonessential genes as antibiotic adjuvants 
(β-lactamase inhibitors are a classical example) (reviewed 
in Wright14), increased understanding of mechanisms of 
bacterial membrane influx and efflux,15,16 and renewed 
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Using Fragment-Based Approaches to 
Discover New Antibiotics
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Abstract
Fragment-based lead discovery has emerged over the past two decades as a successful approach to generate novel lead 
candidates in drug discovery programs. The two main advantages over conventional high-throughput screening (HTS) are 
more efficient sampling of chemical space and tighter control over the physicochemical properties of the lead candidates. 
Antibiotics are a class of drugs with particularly strict property requirements for efficacy and safety. The development of 
novel antibiotics has slowed down so much that resistance has now evolved against every available antibiotic drug. Here 
we give an overview of fragment-based approaches in screening and lead discovery projects for new antibiotics. We discuss 
several successful hit-to-lead development examples. Finally, we highlight the current challenges and opportunities for 
fragment-based lead discovery toward new antibiotics.
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interest in natural products using modern synthetic17–19 and 
bioinformatic tools.20–22
The last two decades have also seen technical advances in 
structure-based drug discovery,23 in particular a variety of 
developments in biophysical techniques.24 These advances 
have supported the evolution of the methods of fragment-
based lead discovery (FBLD), for which there have been 
many reviews.25–27 There is a simple rationale behind the 
testing of fragment-sized compounds, typically with molec-
ular weights of 120–250 Da: fragments cover a large part of 
theoretically possible atom configurations per molecule 
because they contain fewer atoms, and because of their small 
size, they are more likely to bind to a target. Thus, a well-
designed, diverse fragment library contains about a 
thousand- fold fewer compounds than the average high-
throughput screening (HTS) library and covers a consider-
ably larger chemical space. However, fragments bind with a 
much weaker affinity (useful fragments have a dissociation 
constant, K
D
, of up to 2–3 mM) than usual lead compounds, 
and screening relies on the high sensitivity, robustness, and 
throughput of known and new techniques to both identify 
and characterize fragment binding. Once the binding of a 
fragment is confirmed, some initial structure–activity rela-
tionships (SARs) can be explored by the purchase of com-
pounds that are similar to the fragment or contain 
substructures of the fragment (sometimes called SAR by 
catalog). This can increase confidence in the validity of the 
fragment hit, but in general, the process of growing the frag-
ment to a lead compound is challenging without structural 
information generated by either crystallography or nuclear 
magnetic resonance (NMR) experiments. The structure of 
the fragment bound provides ideas about how to evolve the 
structure of the fragment, initially by systematic exploration 
of SARs, making small changes to the core scaffold. For the 
development of the fragment, there are three general strate-
gies, all greatly benefiting from structural information and 
usually supported by biophysical methods to confirm and 
characterize binding: (1) fragment growing, which increases 
potency by optimally engaging the binding pocket, based on 
structural and/or SAR information; (2) fragment linking; 
and (3) fragment merging, in cases where there are two mol-
ecules binding close to each other.
While the main goal of hit-to-lead optimization is to 
increase the affinity or activity of a series, many researchers 
now try to optimize every single atom addition, guided by a 
metric called ligand efficiency (LE),28 which is the average 
binding energy of the molecule per ligand nonhydrogen 
atom (i.e., [–RT ln(K
D
)]/[heavy atom count]). All in all, the 
two core concepts of structure-guided and LE-optimized 
lead design leave relatively little room for serendipity in the 
FBLD process, but instead try to rationally optimize the 
chances and opportunities of finding lead compounds with 
novel scaffolds, favorable physicochemical properties, and 
target selectivity.
In this mini-review, we first summarize the key features 
of the techniques that are used in fragment-based discovery. 
The techniques are primarily considered for their use in 
screening to identify fragments, but the same methods can 
be used throughout the optimization process. We then sum-
marize some of the examples published where the methods 
have been used in antibiotic discovery projects.
Screening Methods in FBLD
A wide range of biophysical, structural, and biochemical 
assays have been used to identify fragments that bind to a 
protein target. Although some targets can have highly 
enclosed binding sites where fragment-sized molecules 
bind with a K
D
 below 1 µM (such as G-protein-coupled 
receptors), most fragment screening campaigns need to 
identify compounds that bind with affinities in the hundreds 
of micromolar to low micromolar range. This places par-
ticular constraints on the screening approach—requiring 
high solubility for the ligands, high sensitivity of the detec-
tion method, and for the assay not to be liable to interfer-
ence from the high concentrations of fragment that are used. 
Most screening campaigns use biophysical methods, usu-
ally with an orthogonal method used for the validation and 
characterization of binding. There have been extensive 
reviews of the different fragment screening methods.26,29,30 
The following is a brief summary of the main characteris-
tics and considerations for each of the screening approaches. 
Key points for consideration of each method are also repre-
sented in Table 1.
Nuclear Magnetic Resonance
There are a wide variety of NMR experiments where the 
spectra obtained are sensitive to the binding of a ligand to a 
protein. There are two main classes of experiments—pro-
tein observed, which detect changes in the spectrum of the 
protein, and ligand observed, which detect changes in the 
spectrum of the ligand, both of which are briefly introduced 
below and described elsewhere in more detail.31–33
Ligand-observed spectra for fragment screening are usu-
ally acquired with a large molar excess of ligand over the 
protein—typically with the protein at 10 µM and the ligand 
at 500 µM. The three most widely used experiments are 
saturation transfer difference (STD),34 water ligand 
observed via gradient spectroscopy (water-LOGSY),35 and 
Carr–Purcell–Meiboom–Gill (CPMG) experiments,36 in 
each of which binding is detected through a change in the 
spectrum of the ligand. For STD, a series of pulses are 
applied at the chemical shift of a core hydrophobic nucleus 
in the protein—this energy is transferred through the pro-
tein, to the ligand, and persists when the ligand dissociates 
into solution. This results in a difference in the spectra mea-
sured for the ligand with and without protein saturation. In 
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water-LOGSY, the energy is transmitted between water 
molecules and ligand molecules. The efficiency of the 
transfer depends on the tumbling speed of the ligand mole-
cules, giving differential signals for free and bound ligands. 
The CPMG experiment more directly measures the tum-
bling time of the ligand, which will be different when bound 
or free. These ligand-observed experiments give no indica-
tion of the site of binding, and because of the high concen-
trations used, it can be possible to obtain false-positive 
results from very weak nonspecific (and often superstoi-
chiometric) binding. For this reason, a competitive step is 
usually included to check for changes to the fragment bind-
ing signal when a known ligand binds to the site of interest. 
In addition, the ligand-observed methods require exchange 
rates (approaching the diffusion limit) that allow the excess 
ligand in a sample to bind at least once to the protein within 
the timescale of the experiment, and so can miss high- 
affinity compounds. Also, the different physical bases of the 
NMR experiments can give rise to artifacts, and for this rea-
son, it can be prudent to require positive signs of competi-
tive binding in all three NMR experiments.37 The advantages 
of these ligand-observed methods are that the protein does 
not need isotopic labeling, there is no limit on the size of the 
protein, and the spectra that are obtained confirm that both 
the protein and the fragment are intact and in solution. The 
main disadvantage is the large amount (typically tens of 
milligrams) of protein required.
The most widely used protein-observed NMR experi-
ment is heteronuclear single-quantum coherence (HSQC), 
which was used in the first published fragment-based dis-
covery project from Abbott.38 Transfer of signal between 1H 
and 15N or 13C in the isotopically labeled protein results in a 
spectrum where each amide or methyl group gives rise to a 
single peak, where the position of each peak depends on the 
local chemical environment, which can be affected by 
ligand binding. The main limitations are the size of protein 
that can be studied (typically 35 kDa), the need for isotopic 
labeling (which is difficult for proteins produced through 
nonbacterial expression), and the need for higher protein 
solubility to give sufficient signal (typically 20–100 µM). 
This requirement also increases the amount of protein 
required for screening. However, the dynamic range of 
HSQC measurements is quite broad, mainly limited by 
compound solubility, although there can be issues at low 
micromolar affinity, where the exchange rates between free 
and bound populations lead to peak broadening. HSQC can 
also give additional information: the pattern of peaks that 
shift can confirm that the fragments are binding to the same 
binding site and, if the spectrum of the protein is assigned, 
then where this binding site is. Also, as long as the ligand is 
soluble, it is possible to titrate and obtain a K
D
 from the size 
of chemical shift on the protein.
A more advanced use of NMR is to determine the bind-
ing mode of the ligand bound to the protein. This requires 
more extensive NMR experiments that give an assignment 
of which peak corresponds to which nucleus, and then col-
lection of sets of distances between the atoms from nuclear 
Overhauser effect (NOE) experiments. A full collection of 
Table 1. Summary of Main Features of Most Widely Used Fragment Screening Methods.
Technique Throughputa
Proteinb 
Consumption
Lower Affinity 
Limit (mM)c Main Limitation Notes
Ligand-observed 
NMR
High High 10 No direct structural 
information
 
Protein-observed 
NMR
Low High 5 Usually limited to proteins 
<35 kDa
 
SPR Moderate Low 0.5 Requires protein 
immobilization
Low false-negative rate
TSA High Low 0.1 Insensitive High false-negative rate
Biochemical assay High Low 0.1 Many ways of interference Direct functional information
Crystallography Moderate Moderate No limit Requires high-quality crystals Low false-positive rate
WAC Low Low 1 Requires protein 
immobilization
Low false-negative rate
MST Moderate Low 0.5 Requires protein labeling  
The comments are somewhat subjective and reflect the experience of the authors but summarize the comments made in the text. All techniques 
depend on the expertise of the user, particularly in recognizing artifacts leading to false-positive or false-negative results. In addition, the limitations are 
affected not only by the sensitivity of the detection method but also by compound behavior (solubility and aggregation).
aThroughput depends on the system and the instrumentation available, but “high,” “moderate,” and “low” are for many hundreds, tens, or a few 
compounds per day.
bFor protein consumption, “high,” “moderate,” and “low” are where a screen of 1000 fragments would require many tens, single-digit, and below 1 mg 
of protein in most cases.
cThe affinity limit, presuming that the compounds have unlimited solubility, is approximately the lowest detection limit for the technique. Note that 
ITC is not used for fragment screening—the protein consumption is too high, the experiment takes too long, and the binding of some fragments is 
entropically driven, so they would be missed.
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NOEs can give a complete structure for the protein with 
ligand bound. A variant is to collect limited NOE data 
(using an isotope-filtered NOE experiment) to identify par-
ticular ligand–protein NOEs that can be used to generate an 
NMR-guided model of how the ligand binds.39 Such 
protein- observed NMR experiments underpinned the frag-
ment discovery work at Abbott.38,40,41
Surface Plasmon Resonance
Surface plasmon resonance (SPR) is a method to measure 
the change in molecular mass when a ligand binds to a pro-
tein. The most widely used equipment uses a surface to 
which either the ligand or the protein is attached—the other 
component is then flowed over the surface. The refractive 
index of light shone onto the surface is sensitive to the 
molecular mass of what is attached. If a protein is immobi-
lized, the increase in mass as the ligand is flowed over gives 
information about the association rate; if the ligand is 
replaced with just buffer, then the dissociation rate can be 
measured. The ratio of the dissociation and association rates 
is the equilibrium constant. The current generation of instru-
ments is sensitive enough to detect the binding of low-
molecular-mass compounds, such as fragments. The main 
issues are in finding the conditions and strategy to immobi-
lize the protein to provide a homogenous surface where the 
protein remains folded and having the reagents (and experi-
ence) to design suitable control experiments to validate the 
system, as summarized in the excellent review from 
Giannetti.42
Thermal Shift Analysis
The principle behind thermal shift analysis (TSA) is that the 
temperature at which a protein unfolds will be changed by 
binding of a ligand. In practice, a protein solution (± the 
ligand) is heated in the presence of a fluorescent dye—the 
dye binds to the hydrophobic surface as the protein unfolds. 
The advantage of the technique is that it uses relatively 
cheap equipment (a qPCR machine is sufficient), uses small 
amounts of protein, and is quite rapid. The method works 
well to identify ligands that stabilize a protein for crystalli-
zation43 and for screening suitable buffers to stabilize the 
protein,44 and has been used for screening libraries of larger 
compounds.45 TSA has been used for fragments, but there 
are issues with many false negatives;46 a weakly binding 
fragment does not necessarily stabilize the protein to a 
detectable level. However, it is a fast and economical way 
of screening, attractive to academic groups.
Biochemical Assay
A biochemical assay (such as a functional enzyme assay or 
a binding assay, such as displacement of a fluorescently 
labeled probe) can be used to screen for fragments. The 
main requirement is that the assay is not compromised by 
the high concentration of ligand (and sometimes associated 
solvent) of ligand being used. The advantage of a functional 
assay over biophysical techniques is that it only reports 
binders that modulate function (functional relevance of hits 
is often unclear, especially from crystallography47) and can 
distinguish between different types of modulators if the 
assay is balanced properly.48 The review in49 includes com-
parison of biochemical and biophysical assays.
Crystallography
There was a strong focus on high-throughput x-ray crystal-
lography for the screening of fragments from some of the 
early adopters of the approach,50 and there have recently 
been significant improvements in streamlining data collec-
tion and structure determination.51 There is an immediate 
advantage in providing a model for the binding of the frag-
ment, and the high concentrations required for soaking 
experiments means quite weak binding fragments can be 
identified. However, it does require the protein to crystal-
lize with an accessible active site and a crystal packing 
resistant to moderate solvent and ligand concentrations. It 
often takes a number of attempts to obtain a crystal struc-
ture of a fragment binding to a protein even when it has 
been confirmed to bind by other techniques.29
Isothermal Titration Calorimetry
An isothermal titration calorimetry (ITC) experiment mea-
sures the heat (enthalpy or ∆H) that is released or taken up 
when a ligand binds to a protein, and the titration gives the 
equilibrium binding constant from which the entropy com-
ponent (∆S) can also be determined. As long as there is 
some heat change on binding, the technique is extremely 
robust and can be used to detect and characterize binding 
for proteins that are difficult to assay in other ways. 
Importantly, it can confirm the stoichiometry of binding. 
However, it is quite expensive in protein and so is not used 
for screening (see the survey on screening methods25). It 
also has high requirements for the solubility of the ligand (if 
titrated).
Other Ideas and Approaches
Many other approaches and technologies have been sug-
gested and used for detecting low-affinity interactions. In 
general, no particular technique can be regarded as a “best-
in-class” solution, but it is useful to be aware of and con-
sider all available options. Some of these other methods 
are proprietary, such as the capillary electrophoresis 
method used by Selcia,52 the target-immobilized NMR 
screening (TINS) method of ZoBio,53 and weak affinity 
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chromatography (WAC).54 Mass spectrometry is limited to 
situations where the ligand binds with affinities better than 
approximately 100 µM, but has been applied successfully 
with covalently bound fragments,55 with the “tethered” 
fragments approach of Sunesis,56 and more generally by 
NovAliX.57 Another recently developed biophysical tech-
nique that has been successfully applied by some to FBLD is 
microscale thermophoresis (MST) (Nanotemper GmbH58). 
In this approach, the mobility of molecules (observed from 
a fluorescent label) along thermal gradients (thermopho-
retic mobility) is used to identify changes in molecular 
hydration and thus molecular interactions.
General Comments on Fragment 
Screening
There is much debate about the “best” technique to use for 
fragment screening (e.g., see the Practical Fragments blog25). 
All the techniques have their pros and cons (see Table 1)—
protein-observed NMR requires labeling and has a size limit, 
ligand-observed NMR requires large amounts of protein, 
x-ray crystallography requires a suitable crystal system, and 
SPR (and MST) requires effective labeling that does not 
affect function. Each of the techniques also has particular 
requirements in terms of the solubility of the protein and the 
solubility of the ligands screened and can robustly detect dif-
ferent dynamic ranges of binding affinity. There are occa-
sionally studies that discuss the different hits obtained from 
fragment screening with different techniques (e.g., Schiebel 
et al.59). However, if the limitations of each technique are 
taken into account (sensitivity, buffers, solubility, etc.), then 
the same hits should be obtained.49,54 One should take cau-
tion if only taking the intersection of hits—this will identify 
the most robust binder but means the diversity of hits is vul-
nerable to the least reliable method. As mentioned before, hit 
validation by orthogonal techniques will filter out some false 
positives when those emerge from limitations of the tech-
niques (e.g., compound intrinsic fluorescence in some types 
of biochemical assay or direct saturation in STD NMR). 
There are still many possible ways in which false positives 
survive orthogonal validation, as drug discovery practitio-
ners became aware of relatively recently,60,61 but there seem 
to be no general rules applicable to all projects.62,63 In the 
end, a balance must be found between false positives and 
false negatives, depending on the goals of the project (taking 
into account scaffold diversity, chemical tractability, etc.).
Examples of Fragment-Based 
Discovery of Antibiotics
Biotin Carboxylase
Bacterial proteins without human homologs have often 
been prioritized as antibacterial targets. However, unbiased 
whole-cell screening has yielded good targets, even when 
homologous to human targets, as in the case of the 
Escherichia coli enzyme biotin carboxylase (BC).64 BC is a 
subunit of the bacterial acetyl-CoA carboxylase that uses 
adenosine triphosphate (ATP) to catalyze the first step of 
the reaction. The ATP binding site of BC has similarities to 
human kinases. Mochalkin et al. followed up on this target 
by using FBLD to discover potent leads with new scaf-
folds.65 They employed a cascade of three screening experi-
ments, summarized in Figure 1. First, a biochemical assay 
that was available from their earlier work64 was used to 
screen ~5000 fragments in mixes of 10. The use of two dif-
ferent, moderate screening concentrations probably helped 
them to recognize artifacts. About 20% of the fragment 
mixes showed inhibition of more than 25%. Then, to iden-
tify the active component(s) of each mix, their binding to 
BC was measured by STD NMR. This resulted in a set of 
142 fragments (3% of the library). Finally, concentration-
dependent inhibition was determined by titration of the 
single compounds in the original enzyme assay.
The fragment screen results were complemented by vir-
tual screening. Out of a set of 2.2 million small organic in-
house compounds (including fragments), a subset was 
selected for 3D similarity to previously identified HTS hit 
1.64 Visual inspection of subsequently generated binding 
poses at the BC ATP binding site yielded 525 hits. This hit 
set was tested in the enzyme assay and contained 48 com-
pounds (9%) inhibiting BC at 50% inhibitory concentration 
(IC
50
) values less than 10 µM. Furthermore, it also con-
tained several active fragments with novel scaffolds (Fig. 1, 
such as fragment 3).
Several of the most potent hits (such as 2) had pharma-
cophore features in common with the earlier identified HTS 
hit 1, and the common binding mode was confirmed from 
co-crystal structures. This information was used to generate 
a number of lead series. For example, fragment 3, a hit from 
both the fragment and virtual screen, could be optimized 
into a potent lead 4 with bactericidal activity. As with 1, its 
specific inhibition of BC could be inferred from reduced 
activity against a spontaneous single-amino-acid substitu-
tion mutant of BC. Interestingly, the HTS- and fragment-
derived leads showed differences in properties like efflux 
pump susceptibility, cell penetration, and activity against 
different Gram-negative pathogens. In addition, the lead 
series were at least 70-fold selective for E. coli BC over a 
panel of more than 30 human kinases.
DNA Gyrase
Bacterial DNA gyrase, a type II topoisomerase, is a tetra-
meric complex that acts on topological isomers of DNA 
during replication and transcription to relieve positive 
supercoiling of double-stranded DNA. This is an essential 
process and proceeds via similar mechanisms in all domains 
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of life. There are several classes of successful bacterial DNA 
gyrase inhibitors (e.g., quinolones, aminocoumarins, and 
novel bacterial type II topoisomerase inhibitors [NBTIs]) 
both on the market and under development, targeting either 
the ATPase domain (GyrB) or the DNA cleavage domain 
(GyrA).
There have been several fragment-based drug discov-
ery campaigns against DNA gyrase. One of the earliest 
examples of FBLD66 used a screening cascade similar to 
that described for BC. First, a selection of small frag-
ments (then called “needles”) was made from a database 
of available compounds by pharmacophore fitting and 
docking into the GyrB ATP binding site. Then, this set of 
3000 fragments was tested for biochemical activity at 
high (0.5 mM) concentration. Finally, a set of 150 hits 
divided over 14 compound classes was taken to the vali-
dation stage, which included a second biochemical assay, 
various biophysical binding experiments (including SPR 
and NMR), and SAR elaboration. Further structure-
guided optimization yielded lead compounds (e.g., 6) 
with up to ~30,000-fold improved inhibitory activity in 
vitro (Fig. 2A).
More recently, researchers at AstraZeneca reported the 
discovery67 of pyrrolamide GyrB inhibitors and their devel-
opment68 into clinical phase. A low-affinity pyrrole carbox-
ylate (7, Fig. 2B) binding in the adenine pocket was 
identified in a protein-observed NMR screen. This fragment 
engages the conserved aspartate + water motif that is also 
exploited by 5 and other GyrB inhibitors. Fragment 7 was 
part of a collection of fragments of known GyrB inhibitors 
that was added to the generic diverse screening library. 
Fragment 7 was chosen as a starting point for elaboration 
based on its favorable LE and growth vectors. Fragment hit 
8, even though very weak and ligand inefficient, was inter-
esting because it bound to the aminocoumarin binding 
region of GyrB, presenting a way for 7 to gain affinity. 
Based on this reasoning, a pyrrolamide library was prepared 
and screened in an E. coli DNA gyrase ATPase assay. A 
1-arylpiperidin-4-yl extension (9) proved to give the best 
increase in activity but was not yet potent enough for cellular 
Figure 1. Screening 
against BC. Fragment and 
virtual screens conducted in 
parallel resulted in several 
highly ligand-efficient 
hits (2, 3) with similar 
pharmacophore features 
to HTS hit 1, and novel 
scaffolds. A number of lead 
series (such as 4) were 
generated that showed 
antimicrobial activity. Red 
dashed circles indicate 
similar pharmacophore 
features.
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activity. Guided by crystal structures of Staphylococcus 
aureus GyrB with bound pyrrolamides, the aromatic group 
was replaced by thiazole 4-carboxylate for optimal interac-
tion with the two arginine side chains close to the amino-
coumarin binding region. Together with a 100-fold increase 
in affinity, lead compound 10 showed not only antibacterial 
but also bactericidal activity against S. aureus, as well as an 
E. coli strain with impaired drug efflux. Further lead opti-
mization eventually focused on the stereochemistry of the 
piperidine ring, which influences protein–ligand interac-
tions via the orientation of the pyrrole and thiazole rings. 
The clinical candidate 11 (AZD5099) was chosen for an 
optimal combination of pharmacokinetic and physical prop-
erties, in part conferred by an intramolecular hydrogen 
bond between the deprotonated carboxylic acid and the 
 secondary amide.68 Unfortunately, development of the 
pyrrolamide lead series was stopped after the first phase I 
study with AZD5099.69
Currently, two new DNA gyrase inhibitors, both discov-
ered during whole-cell screening, are being evaluated by 
Entasis Therapeutics and GlaxoSmithKline in late-stage 
clinical trials for Neisseria gonorrhoeae infections.8
Cell Division Protein FtsZ
FtsZ plays an essential role in the separation of newly form-
ing cells during bacterial replication.70 It is homologous in 
structure to eukaryotic β-tubulin, a cancer target in humans. 
Like tubulin, FtsZ binds guanosine triphosphate to polym-
erize into strands, but FtsZ is only needed for cell division 
and not for chromosome separation. Inhibition of FtsZ does 
not directly stop growth but leads to formation of long 
Figure 2. Hit-to-lead optimization 
of GyrB inhibitors. (A) Indazole (5), 
a validated hit from a virtual screen, 
was optimized to lead compound 6. 
(B) Development of pyrrole hit 7 
into clinical candidate 11. MNEC = 
minimum noneffective concentration; 
MIC
90
 = MIC value at which 90% of 
tested strains were inhibited.
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filaments or large “balloons” that eventually lyse. 
Development of antibacterials targeting FtsZ has been 
ongoing for well over a decade. Most of the reported com-
pounds act by preventing FtsZ polymerization, destabiliz-
ing polymers, or stabilizing polymers.71
Shortly after the discovery of the function of FtsZ,72 the 
protein was reported as the primary target for the fragment-
like microbiological tool compound 3-methoxybenzamide 
(12) (Fig. 3A).73 Seeing this as a starting point for fragment- 
based program, Czaplewski and coworkers optimized the 
methoxybenzamide scaffold to a potent lead compound.74 
PC190723 (13) (Fig. 3A) has exceptional antibacterial 
activity against several S. aureus strains, including multi-
drug-resistant ones.75 Unlike the usual fragment screening 
hits, 12 was already known to be able to penetrate the bacte-
rial cell membrane, and to cause filamentation by acting on 
FtsZ. In the absence of any structural information on how 
12 binds to FtsZ, optimization of the benzamide scaffold 
was done by thorough, systematic SAR only74 (a strategy 
not favored by many FBLD practitioners today). 
Optimization efforts were based on minimum inhibitory 
concentration (MIC) and filamentation against Bacillus 
subtilis. Derivatives with variations on each possible posi-
tion on the scaffold (Fig. 3B) were either bought or synthe-
sized (less than five steps). This early SAR series clearly 
indicated that any substituents larger than a single atom on 
any position except R3 eliminated growth inhibition and 
filamentation in vitro. A hydrophobic group of medium size 
on R3 boosted potency up to 8000 times. Unfortunately, the 
nonyl group of the most potent compound (16) (Fig. 3B) is 
quite un-drug-like. Further optimization eventually yielded 
13, which is active against B. subtilis and S. aureus but not 
other Gram-positive or Gram-negative bacteria.75 Based on 
a resistance mutation profile and an apo structure of FtsZ, 
the researchers suggest that 12 and derived inhibitors bind 
to an allosteric site next to the nucleotide binding site, 
homologous to the Taxol binding site of tubulin. This 
hypothesis was later confirmed by crystallography76 (Fig. 
3A), and this binding mode was shown to promote FtsZ 
polymerization and stabilize FtsZ polymers.77
This compound class is one of the most promising candi-
date antibiotics, even though it has a narrow spectrum (S. 
aureus, including drug-resistant strains) and has proven dif-
ficult to optimize in terms of pharmacokinetic properties.78 
It is currently under active preclinical development by Taxis 
Pharmaceuticals.
EthR
Isoniazid and ethionamide are anti-TB drugs targeting the 
same component of the mycolic acid synthesis pathway 
of mycobacteria. Because effective use of ethionamide 
Figure 3. SAR exploration 
of the benzamide scaffold. 
(A) FtsZ inhibitor 
3-methoxybenzamide (12) 
was the starting point for 
optimization into lead 
compound PC190723 (13), 
which was shown to bind 
in a hydrophobic cleft (PDB 
code 4DXD). Residues that 
confer resistance to 13 
upon mutation are shown 
as raspberry-colored sticks. 
Hydrogen bonds are shown 
as dashed yellow lines. (B) 
Several substituents were 
placed on each R group, 
including combinations of 
two groups on different 
positions. Fil. = minimum 
concentration at which 
filamentation was observed.
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requires high doses associated with liver toxicity, a way to 
lower the required dose would be an attractive therapy. 
Isoniazid and ethionamide have different resistance profiles 
because they are prodrugs activated by different bacterial 
enzymes. Ethionamide is activated by EthA.79 The ethA 
gene is regulated by the transcriptional repressor EthR.80 
Therefore, several drug discovery projects have searched 
for EthR inhibitors as adjuvants for ethionamide. EthR is a 
relatively new anti-TB target with promising early inhibi-
tors, as will be described. It will be interesting to see 
whether EthR inhibitors can be developed into therapies, as 
the role of EthA in ethionamide activation is not yet fully 
understood, as suggested by recent reports of redundant 
mechanisms.81–83
EthR has a deep, narrow, hydrophobic pocket that facili-
tates allosteric deactivation upon compound binding. 
Researchers at the Pasteur Institute found several active hits 
among a small set of compounds selected by pharmaco-
phore modeling.84 After attempting to expand the hits inside 
the binding pocket by in situ click chemistry,85 they took 
one of the click reaction components, 17 (Fig. 4A), as a 
starting point for fragment-based hit-to-lead optimization.86 
Although extension of the original hits with this structure 
did not increase the potency, 17 does display weak potency 
on its own. The fragment was found to bind near the bottom 
of the binding cavity, making the critical hydrogen bond to 
N179 with its sulfonamide group. Based on this binding 
mode, a set of 61 × 16 combinations of commercially avail-
able 4-substituted benzenesulfonyl chlorides and amines 
(respectively) was generated and screened in silico. The 
resulting SAR data were validated in vitro to yield 18 with 
32-fold improved inhibition of EthR DNA binding. 
Encouragingly, the in vitro activity of 18 was matched by its 
ex vivo ability to boost the antibacterial effect of ethion-
amide at 1/10 its MIC. The binding mode of 18 was also 
confirmed by crystallography to match the predicted one. 
Further optimizations included replacement of the sulfon-
amide group with an amide that picks up an additional 
hydrogen bond interaction with N176, leading to a lead 
compound (19) with excellent LE and higher activity than 
its originator, 20. In this example, the fragmentation 
approach has worked well despite 17 adopting a different 
binding mode (Fig. 4B) than expected (from that of 20, Fig. 
4C) and also lacking the previously identified core 
scaffold.84
Fragment screening against EthR has produced another 
interesting series of compounds. Noting that the allosteric 
pocket of EthR is hydrophobic, Surade and colleagues used 
Figure 4. Fragmentation approach 
for EthR inhibitors. (A) Click 
reaction component 17 can be seen 
as a fragment with weak activity. It 
was successfully grown via virtual 
(18) and then actual medicinal 
chemistry to lead compound 19. 
(B) Crystal structure (PDB code 
4M3B86) showing the binding mode 
of 19 (green sticks) in the M. 
tuberculosis EthR allosteric pocket 
(grey surface representation). The 
binding pose of 20 (cyan thin lines) 
in the same pocket (PDB code 
3O8H85) is overlaid. (C) Crystal 
structure (PDB code 3O8H) 
showing the binding mode of 20 
(cyan sticks) in its binding pocket 
(grey surface). The binding pose 
of 19 (green thin lines) in the 
same pocket (PDB code 4M3B) 
is overlaid. Hydrogen bonds are 
shown as dashed yellow lines. 
EC
50
 = concentration of EthR ligand 
at which M. tuberculosis growth in 
macrophages is inhibited by 50% 
by ethionamide at 1/10 of its MIC, 
determined according to a standard 
procedure.106
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TSA to identify 86 hits from a library of 1250 fragments, 
some of which stabilize EthR by more than 5 °C.87 The hits 
were validated using orthogonal biophysical techniques. As 
mentioned earlier, it is not trivial to select the best primary 
and secondary screening techniques and to interpret their 
combined data, as each technique has its own false-positive 
or false-negative rates and can be more suitable for certain 
screening subjects or libraries than others.88 In this case, 
SPR validation data agreed well with the primary screen, 
with only 1 out of 45 negative controls (nonhits from TSA) 
showing up as an inhibitor in SPR. Only slightly more than 
half of the 86 TSA hits were identified as inhibitors, perhaps 
because of the large difference in assay concentrations (10 
mM in TSA vs 0.5 mM in SPR). Several validated hits were 
soaked into EthR crystals to elucidate their binding modes. 
Interestingly, three hits contained similar arylsulfone scaf-
folds, as discussed in the previous example, with their sul-
fone groups interacting with N179. A fourth hit, 21 (Fig. 5), 
however, was more interesting because of its ability to 
occupy a second subpocket in the crystals, as well as the 
hydrophobic cavity simultaneously. Linking the two slightly 
modified molecules together to form 22 dramatically 
decreased the IC
50
. However, notably, the in vitro antibacte-
rial potencies of these two compounds are identical, show-
ing that straightforward optimization of binding strength 
and LE is not always an effective strategy. Indeed, further 
fragment merging efforts monitored solely by biophysical 
techniques were unsuccessful.89 The authors suggest that 
decreased compound membrane permeability might explain 
the discrepancy. Instead, SAR exploration around hit 20, 
while staying within fragment size range, monitored by ITC 
as well as bacterial growth assays, yielded submicromolar 
ethionamide boosters such as 23.90
E-Lactamase
Evolution of plasmid-based β-lactamases to confer resis-
tance to standard antibiotics was one of the first signs of a 
new era in healthcare. As the problem grew, inhibitors of 
β-lactamases (another example of adjuvants) were being 
used in hospital settings but not to great effect.91 First-
generation inhibitors like the natural product clavulanic 
acid, themselves β-lactams, quickly lost effectiveness due 
to resistance and narrow activity spectrum. Another class of 
β-lactamase inhibitors is boronic acids. Although their 
effects were noted since the 1980s and gained interest from 
researchers, no boronic acids entered clinical use until very 
recently, with the Food and Drug Administration’s (FDA) 
approval of a combination therapy of vaborbactam with a 
carbapenem for urinary tract infections.
Sulfonamide boronic acids are another recently devel-
oped class of β-lactamase inhibitors. As with vaborbac-
tam,92 early discovery and optimization of these molecules 
were guided by docking and modeling.93,94 Although sev-
eral compounds in this series displayed high in vitro inhibi-
tory activities, their effects on the antibacterial properties of 
β-lactamase-sensitive cephalosporins were only modest and 
did not follow the same trends. Reasoning that increasing 
β-lactamase affinities even further could solve the problem, 
the researchers made an in-depth analysis of possible enzyme–
ligand interactions using results from virtual fragment screens 
and known inhibitor fragmentation approaches.95 Bound 
fragments can give great insight into the characteristics of 
the interactions of larger ligands, because fragment binding 
modes are unconstrained by distant binding pocket geome-
tries. Thus, with encouraging modeling results, lead inhibi-
tor 24 could be modified to optimize the conformation of its 
benzyl group and to pick up an extra hydrogen bond (com-
pound 25, Fig. 6A). Furthermore, fragment screens can effi-
ciently offer insights into viable alternative chemical space, 
as shown by the model-guided replacement of the carboxyl-
ate of 24 by a tetrazole moiety, yielding 26, which retains 
similar affinity and interactions as 25 (Fig. 6B). Interestingly, 
while both 25 and 26 were active as β-lactamase inhibitors 
in cellular assays, they showed slightly different profiles, 
probably due to their differing physicochemical properties. 
Most pronounced was the difference in ability of these com-
pounds to also inhibit a class A β-lactamase, an effect to 
which no special effort was made during the optimization 
process. A close derivative of 26 also promoted the survival 
Figure 5. Fragment screening 
derived inhibitors of EthR. n.d. = not 
determined.
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of infected mice when treated with a β-lactamase-sensitive 
cephalosporin, although to a lesser degree (65%) than could 
be reached with a β-lactamase-resistant carbapenem (90%).
Discussion
Not enough novel antibiotics have entered the market to 
mitigate the threat of AR. It appears that the challenge of 
developing antibiotics is a particularly difficult one, and 
there have been several explanations for this: biased screen-
ing libraries (both synthetic and organism-derived natural 
products)96 and inadequate target selection, validation,11,97 
or screening methods.98 Apart from these, the fact remains 
that antibiotics development is more difficult because of the 
extra barriers that bacteria present between a drug and its 
target, such as additional and different (from human) cell 
membranes, drug efflux, and metabolism systems. Possible 
solutions to these problems have been proposed, though 
Figure 6. Fragments guide lead derivatization of E-lactamase inhibitors. (A) Lead compound 24 (dark grey) was successfully modified 
to 25 (light grey) to pick up an extra hydrogen bond with residue G320 of E. coli AmpC, inspired by a fragment (orange) binding pose 
(figures prepared using structures deposited with PDB codes 3O87,94 2HDR,107 and 4E3I,95 for binding poses of 24, the carboxylate 
fragment, and 25, respectively). (B) The same interactions are made by 26 (light grey), modified to incorporate a tetrazole moiety, 
as suggested by another fragment (magenta) (figures prepared using structures deposited with PDB codes 3O87, 3GR2,108 and 4E3J,95 
for binding poses of 24, the tetrazole fragment, and 26, respectively). Hydrogen bonds are shown as dashed yellow lines. AmpC = 
fold reduction in MIC of cefotaxime against a strain of E. coli overexpressing class C E-lactamase AmpC, when the compound was 
added at a 1:4 ratio of cefotaxime to E-lactamase inhibitor; CTX-M = fold reduction in MIC of cefotaxime against a strain of E. coli 
overexpressing class A E-lactamase CTX-M-14, when the compound was added at a 1:4 ratio of cefotaxime to E-lactamase inhibitor.
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most of them too recently to influence the antibiotics pipe-
line yet. For example, important aspects of drug efflux 
mechanisms have been elucidated,99–101 allowing more 
rational design of inhibitors and other antibiotics. Similarly, 
past successful and failed antibiotics give insight into their 
properties that are important for membrane perme-
ation.15,102,103 However, all these aspects still put extra con-
straints on a drug’s properties. Additionally, to address the 
risk of rapid development of resistance, antibiotics must 
have exceptional efficacy and low toxicity. A hit might be 
modified so heavily to address all these issues that some of 
the original properties are lost, or worse, the hit properties 
conveying efficacy are incompatible with those needed for 
good permeability, stability, and safety. Though this might 
seem exacerbated in the case of fragment-based hits, FBLD 
could offer an advantage by having a higher chance of gen-
erating other lead scaffolds (which is why we prefer the 
term fragment-based lead discovery). The process from 
lead to candidate is much the same, by whichever method a 
lead was found.
Recently, different approaches to screening for antibac-
terials have been explored, including exploration of natural 
products from uncultured bacteria104 and target-based 
whole-cell screening.98 Here various FBLD approaches in 
antibiotic lead discovery have been discussed. One of the 
principles of FBLD is that it is target based. Given a target, 
FBLD can be used to efficiently generate leads with control 
over desired properties, such as lipophilicity and selectivity. 
For example, for GyrB, fragment screening was a good 
choice because it offered a way of finding new compounds 
for a validated mechanism of action. The fragment hit 7 is a 
feature of clorobiocin, a member of the aminocoumarin 
class of gyrase inhibitors, which are very potent but also 
have toxicity and solubility issues. The FBLD optimization 
strategy, using structural information and concepts such as 
LE, yielded a potent lead that even progressed to clinical 
candidate.
In the case of GyrB leads 6 and 10, and in the cases of 
EthR lead 18 and β-lactamase leads 25/26, it was fortunate 
that FLBD-guided increases in target affinity also resulted in 
whole-cell activity. Unfortunately, many other antibacterial 
discovery projects have shown that this cannot always be 
achieved. Especially for FBLD antibacterial projects, most 
of which in the early stages are carried out entirely in vitro 
with purified protein, it is important to keep an eye on the 
potential to gain whole-cell activity, as soon as reasonable 
progress after hit validation has been made. This was one of 
the key strategies for successful optimization of EthR frag-
ment screening hit 21 into 23 with cellular potency.
In some cases, such as cell division protein target FtsZ, 
target-based whole-cell screening can even start from the 
fragment stage. The development of FtsZ inhibitor 13 is an 
unusual example of fragment-based projects because no 
screening was involved, no structural information was 
available, and the starting fragment 12 already showed spe-
cific activity in cells. Rigorous medicinal chemistry efforts 
were made applying principles important for every fragment-
based project, especially the thorough characterization of the 
fragment scaffold. Small changes can have great impact on 
the activity of scaffolds, as evident for fragment 15 compared 
with 12 (as well as for EthR inhibitor 23 compared with 21). 
However, the useful metric of LE cannot be used when MICs 
are the primary measure of potency. Indeed, it would not be 
easy to establish any SAR in these cases without a very spe-
cific target inhibition phenotype, because changes in MIC 
could also come from off-target effects.
There have recently been some exciting demonstrations 
of using fragments as probes for target identification in phe-
notypic screening. Off-target effects are expected because of 
the small size of the fragment, but it should have different 
affinities for the various targets, allowing the major targets 
to be identified. A recent example is where each of the frag-
ments in the library is attached to a photoactivatable group—
this covalently links the fragment to a target(s), which is 
then analyzed by mass spectrometry, together with methods 
of stable isotope labeling with amino acids in cells.105 This 
could essentially be described as whole-cell screening with 
direct detection of target binding and has generated a lot of 
interest. It will be interesting to see if this idea of functional 
screening of fragment libraries is successful in identifying 
new targets for antibiotic drug discovery.
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